These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 29360195

  • 21. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 22. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

  • 23. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 24. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.
    Clin Transplant; 2013 Feb; 27(4):503-9. PubMed ID: 23731387
    [Abstract] [Full Text] [Related]

  • 25. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 26. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 27. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
    Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.
    Am J Transplant; 2011 Nov; 11(11):2453-62. PubMed ID: 21812923
    [Abstract] [Full Text] [Related]

  • 28. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [Abstract] [Full Text] [Related]

  • 29. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP, Felipe CR, Prizmic PSS, de Azevedo VFD, Viana LA, Tavares MG, Wagner de Castro Lima Santos D, de Paula MI, Medina-Pestana JO, Tedesco-Silva Junior H.
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [Abstract] [Full Text] [Related]

  • 30. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
    Hellemans R, Wijtvliet V, Bergs K, Philipse E, Vleut R, Massart A, Couttenye MM, Matheeussen V, Abramowicz D.
    Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
    [Abstract] [Full Text] [Related]

  • 31. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

  • 32. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 33. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 15; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 34. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M, Remport A, Hídvégi M, Péter A, Kóbori L, Telkes G, Fazakas J, Gerlei Z, Sárváry E, Sulyok B, Járay J.
    Transpl Infect Dis; 2005 Jun 15; 7(2):63-7. PubMed ID: 16150092
    [Abstract] [Full Text] [Related]

  • 35. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L, Helou S, Bachelet T, Martin S, Moreau K, Morel D, Lafon ME, Garrigue I, Merville P.
    Transplant Proc; 2012 Nov 15; 44(9):2809-13. PubMed ID: 23146529
    [Abstract] [Full Text] [Related]

  • 36. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
    Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP.
    Transpl Infect Dis; 2011 Jun 15; 13(3):244-9. PubMed ID: 21414119
    [Abstract] [Full Text] [Related]

  • 37. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J.
    Transpl Immunol; 2019 Oct 15; 56():101226. PubMed ID: 31344441
    [Abstract] [Full Text] [Related]

  • 38. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.
    Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, Pedersen RA, Dierkhising RA, Patel R, Razonable RR.
    J Heart Lung Transplant; 2007 Oct 15; 26(10):1019-24. PubMed ID: 17919622
    [Abstract] [Full Text] [Related]

  • 39. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C, Rostaing L, Weclawiak H, Rossignol C, Kamar N, Izopet J.
    J Med Virol; 2015 May 15; 87(5):836-44. PubMed ID: 25655981
    [Abstract] [Full Text] [Related]

  • 40. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep 15; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.